Skip to main content

NASDAQ:STRO - Sutro Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.33
  • Forecasted Upside: 17.19 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$19.91
▲ +0.62 (3.21%)
1 month | 3 months | 12 months
Get New Sutro Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STRO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.33
▲ +17.19% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is $23.33, with a high forecast of $37.00 and a low forecast of $17.00. The average price target represents a 17.19% upside from the last price of $19.91.

Buy

The current consensus among 6 polled investment analysts is to buy stock in Sutro Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/15/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/13/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/11/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/10/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/28/2021TruistBoost Price Target$24.00 ➝ $37.00Medium
i
12/2/2020Stifel NicolausInitiated CoverageBuy$25.00Low
i
11/6/2020Piper SandlerBoost Price TargetOverweight$20.00 ➝ $22.00Low
i
9/2/2020Jefferies Financial GroupInitiated CoverageBuy$21.00High
i
7/16/2020Wells Fargo & CompanyInitiated CoverageOverweight$18.00High
i
5/18/2020Piper SandlerLower Price Target$23.00 ➝ $20.00Medium
i
5/13/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $17.00Low
i
5/12/2020B. RileyDowngradeHoldLow
i
Rating by Mayank Mamtani at B. Riley
3/17/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/16/2020CowenReiterated RatingBuyHigh
i
1/13/2020SunTrust BanksInitiated CoverageBuy$18.00Low
i
10/30/2019WedbushReiterated RatingOutperformMedium
i
Rating by D. Nierengarten at Wedbush
10/21/2019HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/7/2019BTIG ResearchInitiated CoverageBuy$19.00High
i
9/5/2019JMP SecuritiesReiterated RatingMarket Outperform$16.00Medium
i
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$22.00High
i
6/24/2019HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/16/2019CowenReiterated RatingBuyLow
i
5/17/2019HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/16/2019CowenReiterated RatingBuyLow
i
5/7/2019HC WainwrightReiterated RatingBuy$18.00High
i
Rating by D. Chattopadhyay at HC Wainwright
4/29/2019HC WainwrightInitiated CoverageBuy ➝ Buy$18.00High
i
Rating by D. Chattopadhyay at HC Wainwright
3/4/2019WedbushBoost Price TargetOutperform$20.00 ➝ $22.00Low
i
Rating by D. Nierengarten at Wedbush
10/22/2018CowenInitiated CoverageOutperformMedium
i
10/22/2018WedbushInitiated CoverageOutperform ➝ Outperform$20.00Medium
i
Rating by D. Nierengarten at Wedbush
10/22/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$28.00Medium
i
10/22/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$23.00Medium
i
(Data available from 5/10/2016 forward)
Sutro Biopharma logo
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $19.91
$18.47
$20.28

50 Day Range

MA: $21.41
$18.52
$24.96

52 Week Range

Now: $19.91
$7.06
$28.30

Volume

10,822 shs

Average Volume

508,768 shs

Market Capitalization

$917.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Sutro Biopharma?

The following Wall Street research analysts have issued stock ratings on Sutro Biopharma in the last twelve months: B. Riley, HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, Stifel Nicolaus, TheStreet, Truist, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for STRO.

What is the current price target for Sutro Biopharma?

6 Wall Street analysts have set twelve-month price targets for Sutro Biopharma in the last year. Their average twelve-month price target is $23.33, suggesting a possible upside of 17.2%. Truist has the highest price target set, predicting STRO will reach $37.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for Sutro Biopharma in the next year.
View the latest price targets for STRO.

What is the current consensus analyst rating for Sutro Biopharma?

Sutro Biopharma currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STRO will outperform the market and that investors should add to their positions of Sutro Biopharma.
View the latest ratings for STRO.

What other companies compete with Sutro Biopharma?

How do I contact Sutro Biopharma's investor relations team?

Sutro Biopharma's physical mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company's listed phone number is 650-392-8412 and its investor relations email address is [email protected] The official website for Sutro Biopharma is www.sutrobio.com.